Renalytix Plc

Third-quarter fiscal 2024 revenue was $535,000, down from $724,000 in the prior-year quarter. GAAP operating expenses were $6.5 million, down 40% from $11 million a year ago, and net loss was $7.7 million, or $0.08 per share, versus about $12.1 million, or $0.14 per share, last year. The company processed 806 tests in the quarter, with 82% billable. Cash was approximately $4.7 million at March 31, before about $6.4 million in net proceeds from the second tranche of the March PIPE and $1.5 million from the registered direct placement announced last month; aggregate gross proceeds from those financings were $13.5 million. Management did not provide formal revenue or EPS guidance, but said the FDA de novo product is now onboarded with other providers, the final LCD could come sooner than September, and they expect continued growth in direct-to-physician ordering and broader payer coverage over 2024.

James McCullough framed the quarter around three major milestones: guideline inclusion, a draft LCD, and the FDA launch of KidneyIntelX.dkd. His tone was highly confident and repetitive about the size of the market, saying the company has now “checked all the boxes” for broader adoption and that the business is becoming a more defensible, high-barriers-to-entry diagnostics platform. He also stressed that the strategic process is active and that the company has added runway through financings and expense cuts, giving it optionality to stay independent or pursue a transaction.

James Sterling focused on the numbers and on cost discipline. He said revenue was $535,000, operating expenses were $6.5 million, net loss was $7.7 million or $0.08 per share, and cash was $4.7 million at quarter-end; he also noted the company raised $13.5 million gross across recent financings and that cash burn is now under $5 million per quarter, about 40% below the second quarter and half of a year ago. He emphasized that billable tests were 82% of the 806 tests processed, that Medicare payment from NGS has continued consistently, and that the company is continuing to control spend without slowing revenue growth.

Analysts focused on when guideline and LCD changes would translate into higher test volumes, what is holding back broader adoption, and whether the company could reach cash-flow breakeven. Management said the biggest barrier remains patient identification and workflow friction inside physician offices, not the clinical story, and pointed to ordering-process changes, simpler requisitions, and better phlebotomy access as ways to improve conversion. On the financial side, management declined to forecast breakeven or volume ramp timing, but said the path for rising volumes exists and that the current sales team is still only one quarter into its new structure.